Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4321503 | 1.00 | HCRTR2 (0.88) | HCRTR2HCRTR1 | |
| SCHEMBL4310014 | 0.85 | HCRTR1 (0.88) | HCRTR2HCRTR1 | |
| SCHEMBL4313183 | 0.85 | HCRTR2 (0.91) | HCRTR2HCRTR1 | |
| SCHEMBL4307333 | 0.85 | HCRTR2 (0.91) | HCRTR2HCRTR1 | |
| SCHEMBL4318520 | 0.85 | HCRTR2 (0.91) | HCRTR2HCRTR1 | |
| SCHEMBL22896773 | 0.85 | HCRTR2 (0.91) | HCRTR2HCRTR1 | |
| SCHEMBL18910770 | 0.83 | HCRTR2 (1.00) | HCRTR2HCRTR1 | |
| SCHEMBL27029839 | 0.83 | HCRTR1 (0.71) | HCRTR2HCRTR1 | |
| SCHEMBL30749372 | 0.83 | HCRTR1 (0.71) | HCRTR2HCRTR1 | |
| SCHEMBL4317720 | 0.82 | HCRTR1 (1.00) | HCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049110-B1 | BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-08-20 | — | — | EP | claimed |
| US-20090239843-A1 | Bridged diazepan orexin receptor antagonists | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | claimed |
| EP-2049110-B1 | BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-08-20 | — | — | EP | disclosed |
| US-8618102-B2 | Bridged diazepan orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-12-31 | — | — | US | disclosed |
| US-20090239843-A1 | Bridged diazepan orexin receptor antagonists | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
| US-20090239843-A1 | Bridged diazepan orexin receptor antagonists | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
| US-20090239843-A1 | Bridged diazepan orexin receptor antagonists | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
| WO-2008008517-A2 | BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239843-A1 | Bridged diazepan orexin receptor antagonists | HCRTR2, HCRTR1, CRHR1 | HCRTR2 1/4885HCRTR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.